Please login to the form below

Not currently logged in
Email:
Password:

glasdegib

This page shows the latest glasdegib news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Pfizer gets first FDA nod for hedgehog inhibitor in AML

The US regulator cleared Daurismo ( glasdegib) for use in combination with low-dose cytarabine for patients with newly-diagnosed AML – aged 75 or over – who are too frail to be treated ... Analysts at Credit Suisse have previously predicted that

Latest news

  • Pfizer's SMO inhibitor boosts survival in blood cancer trial Pfizer's SMO inhibitor boosts survival in blood cancer trial

    Pfizer's glasdegib has become the first SMO inhibitor to show a benefit in two haematological malignancies, boosting overall survival in a phase II trial. ... Glasdegib (previously known as PF-04449913) extended overall survival in patients with acute

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics